Advertisement

Topics

COMPASS: Rivaroxaban Success in Secondary CV Prevention

04:52 EDT 27 Aug 2017 | Medscape

The combination of a low dose of the factor Xa inhibitor rivaroxaban in combination with aspirin was associated with a reduction in ischemic events and mortality and a superior net clinical benefit, balancing the bleeding risk in patients with stable atherosclerotic disease.
Medscape Medical News

Original Article: COMPASS: Rivaroxaban Success in Secondary CV Prevention

NEXT ARTICLE

More From BioPortfolio on "COMPASS: Rivaroxaban Success in Secondary CV Prevention"

Quick Search
Advertisement